Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
5140 | 1666 | 47.3 | 90% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
204 | 3 | PROTEASOME//UBIQUITIN//UNFOLDED PROTEIN RESPONSE | 52492 |
677 | 2 | PROTEASOME//UBIQUITIN//PROTEASOME INHIBITOR | 13186 |
5140 | 1 | PROTEASOME INHIBITOR//BORTEZOMIB//PROTEASOME | 1666 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | PROTEASOME INHIBITOR | authKW | 1649799 | 17% | 31% | 290 |
2 | BORTEZOMIB | authKW | 1338082 | 21% | 21% | 348 |
3 | PROTEASOME | authKW | 303705 | 16% | 6% | 268 |
4 | CARFILZOMIB | authKW | 271458 | 2% | 37% | 40 |
5 | PROTEASOME INHIBITION | authKW | 257680 | 3% | 25% | 57 |
6 | PS 341 | authKW | 247754 | 2% | 52% | 26 |
7 | SYRBACTIN | authKW | 164941 | 1% | 100% | 9 |
8 | MARIZOMIB | authKW | 164935 | 1% | 75% | 12 |
9 | CEP 18770 | authKW | 109961 | 0% | 100% | 6 |
10 | OPROZOMIB | authKW | 109961 | 0% | 100% | 6 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 8874 | 38% | 0% | 638 |
2 | Chemistry, Medicinal | 2505 | 12% | 0% | 201 |
3 | Hematology | 1648 | 10% | 0% | 171 |
4 | Pharmacology & Pharmacy | 721 | 14% | 0% | 240 |
5 | Biochemistry & Molecular Biology | 532 | 19% | 0% | 313 |
6 | Cell Biology | 418 | 10% | 0% | 167 |
7 | Chemistry, Organic | 220 | 7% | 0% | 114 |
8 | Medicine, Research & Experimental | 57 | 3% | 0% | 57 |
9 | Immunology | 48 | 5% | 0% | 76 |
10 | Biophysics | 15 | 2% | 0% | 38 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | INTEGRATED PROT SCI | 54769 | 2% | 9% | 33 |
2 | ZENTRUM MED BIOTECHNOL | 52172 | 1% | 19% | 15 |
3 | LEHRSTUHL BIOCHEM | 44010 | 2% | 10% | 25 |
4 | BIOMETRY STAT ANAL | 41234 | 0% | 75% | 3 |
5 | JEROME LIPPER MULTIPLE MYELOMA | 38065 | 1% | 9% | 24 |
6 | MED STUDY PROGRAM | 36654 | 0% | 100% | 2 |
7 | VATAN CLIN | 36654 | 0% | 100% | 2 |
8 | JEROME LIPPER MYELOMA MED ONCOL | 35238 | 0% | 38% | 5 |
9 | EDUC DRUG DISCOVERY | 31570 | 1% | 19% | 9 |
10 | FRED WYSZKOWSKI CANC | 27336 | 1% | 15% | 10 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | MOLECULAR CANCER THERAPEUTICS | 6114 | 2% | 1% | 37 |
2 | CLINICAL CANCER RESEARCH | 3935 | 3% | 0% | 57 |
3 | CHEMISTRY & BIOLOGY | 1958 | 1% | 1% | 17 |
4 | CURRENT CANCER DRUG TARGETS | 1545 | 1% | 1% | 9 |
5 | INVESTIGATIONAL NEW DRUGS | 1383 | 1% | 1% | 14 |
6 | JOURNAL OF MEDICINAL CHEMISTRY | 1370 | 2% | 0% | 41 |
7 | CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1282 | 1% | 0% | 23 |
8 | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 1157 | 2% | 0% | 41 |
9 | CANCER BIOLOGY & THERAPY | 1081 | 1% | 0% | 13 |
10 | JOURNAL OF ANTIBIOTICS | 1067 | 1% | 0% | 20 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | PROTEASOME INHIBITOR | 1649799 | 17% | 31% | 290 | Search PROTEASOME+INHIBITOR | Search PROTEASOME+INHIBITOR |
2 | BORTEZOMIB | 1338082 | 21% | 21% | 348 | Search BORTEZOMIB | Search BORTEZOMIB |
3 | PROTEASOME | 303705 | 16% | 6% | 268 | Search PROTEASOME | Search PROTEASOME |
4 | CARFILZOMIB | 271458 | 2% | 37% | 40 | Search CARFILZOMIB | Search CARFILZOMIB |
5 | PROTEASOME INHIBITION | 257680 | 3% | 25% | 57 | Search PROTEASOME+INHIBITION | Search PROTEASOME+INHIBITION |
6 | PS 341 | 247754 | 2% | 52% | 26 | Search PS+341 | Search PS+341 |
7 | SYRBACTIN | 164941 | 1% | 100% | 9 | Search SYRBACTIN | Search SYRBACTIN |
8 | MARIZOMIB | 164935 | 1% | 75% | 12 | Search MARIZOMIB | Search MARIZOMIB |
9 | CEP 18770 | 109961 | 0% | 100% | 6 | Search CEP+18770 | Search CEP+18770 |
10 | OPROZOMIB | 109961 | 0% | 100% | 6 | Search OPROZOMIB | Search OPROZOMIB |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | MICALE, N , SCARBACI, K , TROIANO, V , ETTARI, R , GRASSO, S , ZAPPALA, M , (2014) PEPTIDE-BASED PROTEASOME INHIBITORS IN ANTICANCER DRUG DESIGN.MEDICINAL RESEARCH REVIEWS. VOL. 34. ISSUE 5. P. 1001 -1069 | 148 | 75% | 6 |
2 | KISSELEV, AF , VAN DER LINDEN, WA , OVERKLEEFT, HS , (2012) PROTEASOME INHIBITORS: AN EXPANDING ARMY ATTACKING A UNIQUE TARGET.CHEMISTRY & BIOLOGY. VOL. 19. ISSUE 1. P. 99 -115 | 92 | 65% | 186 |
3 | GENIN, E , REBOUD-RAVAUX, M , VIDAL, J , (2010) PROTEASOME INHIBITORS: RECENT ADVANCES AND NEW PERSPECTIVES IN MEDICINAL CHEMISTRY.CURRENT TOPICS IN MEDICINAL CHEMISTRY. VOL. 10. ISSUE 3. P. 232-256 | 131 | 64% | 63 |
4 | RENTSCH, A , LANDSBERG, D , BRODMANN, T , BULOW, L , GIRBIG, AK , KALESSE, M , (2013) SYNTHESIS AND PHARMACOLOGY OF PROTEASOME INHIBITORS.ANGEWANDTE CHEMIE-INTERNATIONAL EDITION. VOL. 52. ISSUE 21. P. 5450-5488 | 109 | 47% | 32 |
5 | BECK, P , DUBIELLA, C , GROLL, M , (2012) COVALENT AND NON-COVALENT REVERSIBLE PROTEASOME INHIBITION.BIOLOGICAL CHEMISTRY. VOL. 393. ISSUE 10. P. 1101 -1120 | 74 | 70% | 26 |
6 | CHEN, D , FREZZA, M , SCHMITT, S , KANWAR, J , DOU, QP , (2011) BORTEZOMIB AS THE FIRST PROTEASOME INHIBITOR ANTICANCER DRUG: CURRENT STATUS AND FUTURE PERSPECTIVES.CURRENT CANCER DRUG TARGETS. VOL. 11. ISSUE 3. P. 239 -253 | 74 | 48% | 212 |
7 | RUSSO, A , BRONTE, G , FULFARO, F , CICERO, G , ADAMO, V , GEBBIA, N , RIZZO, S , (2010) BORTEZOMIB: A NEW PRO-APOPTOTIC AGENT IN CANCER TREATMENT.CURRENT CANCER DRUG TARGETS. VOL. 10. ISSUE 1. P. 55-67 | 62 | 85% | 17 |
8 | HUBER, EM , GROLL, M , (2012) INHIBITORS FOR THE IMMUNO- AND CONSTITUTIVE PROTEASOME: CURRENT AND FUTURE TRENDS IN DRUG DEVELOPMENT.ANGEWANDTE CHEMIE-INTERNATIONAL EDITION. VOL. 51. ISSUE 35. P. 8708-8720 | 72 | 60% | 49 |
9 | GRAWERT, MA , GROLL, M , (2012) EXPLOITING NATURE'S RICH SOURCE OF PROTEASOME INHIBITORS AS STARTING POINTS IN DRUG DEVELOPMENT.CHEMICAL COMMUNICATIONS. VOL. 48. ISSUE 10. P. 1364 -1378 | 79 | 59% | 21 |
10 | MOMOSE, I , KAWADA, M , (2016) THE THERAPEUTIC POTENTIAL OF MICROBIAL PROTEASOME INHIBITORS.INTERNATIONAL IMMUNOPHARMACOLOGY. VOL. 37. ISSUE . P. 23 -30 | 66 | 65% | 1 |
Classes with closest relation at Level 1 |